Explore more publications!

Press Releases

Under President Trump and Secretary Noem, the Department of Homeland Security Has Historic Year

Under President Trump and Secretary Noem, the Department of Homeland Security Has Historic Year

MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
ZenaTech Signs Offer to Acquire a Surveying Firm in the US West Expanding Drone as a Service Footprint to Serve Precision Agriculture, Ranching and Wildfire Management
Governor Newsom announces $47 million in grants to help prevent substance use among California youth, including supports for struggling young men and boys

Governor Newsom announces $47 million in grants to help prevent substance use among California youth, including supports for struggling young men and boys

Governor Newsom provides communities $52 million to build housing and infrastructure, address homelessness

Governor Newsom provides communities $52 million to build housing and infrastructure, address homelessness

ZenaTech Enters UK Market Closing Drone-as-a-Service Acquisition of Casado Design Ltd., Expanding to the Growing Telecom Tower Design and Infrastructure Sector
AUVSI Accredits New Training Providers Under Trusted UMS Operator™ Program, Expanding Maritime Workforce Standards
Drop-off centres open to get batteries out of bins and reduce fire risk

Drop-off centres open to get batteries out of bins and reduce fire risk

CS195 Metal Fireproof Expansion Joint Boards: JunYihao’s Commitment to Safety Excellence
CBP officers at South Texas Ports of Entry in FY 2025 amassed a 62 percent increase in hard narcotics seized over FY 2024

CBP officers at South Texas Ports of Entry in FY 2025 amassed a 62 percent increase in hard narcotics seized over FY 2024

MediPharm Labs Completes First Shipment to France
Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
Tilray Releases the Ultimate 2025 Holiday Drink Gift Guide, Celebrating Seasonal Sips and Moments of Connection from Coast to Coast
NorCal Holistics Continues Expansion Into Four Greater Sacramento Areas
Washington State Bowling Proprietors’ Association Announces 2026 Legislative Priorities
ZenaTech Expands Drone as a Service to Australia with Offer to Acquire a Survey Firm Serving Government and Natural Resources and Commercial Sectors
Addiction Policy Forum Highlights 10 Recent Breakthroughs and Studies Advancing Understanding of Addiction and Treatment

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions